Acusphere(OTC) ACUS

Acusphere, Inc. is a pharmaceutical company focused on developing and commercializing innovative cardiovascular treatments. The company's flagship product, Imagify, is designed to assess myocardial perfusion and assist in diagnosing coronary artery disease.

Products and Services

• Imagify: A cardiovascular medication for myocardial perfusion assessment
• Injectable suspension formulation for enhanced delivery
• Research and development of additional cardiovascular therapies

Growth Outlook

• Continued focus on expanding the cardiovascular treatment market
• Potential for new product development in the pipeline
• Strategic partnerships may enhance market reach and capabilities

Financial Highlights

• Recent quarterly revenue of 339,000, showing product demand
• Operating income margin of 29.31%, indicating operational efficiency
• Cash and cash equivalents of 4,112,000, providing liquidity for operations

Acusphere, Inc. operates within the healthcare sector, specifically in the drug manufacturing industry, with a focus on specialty and generic drugs. The company has a history of innovation, having been established in 1993 and rebranded in 2004. The flagship product, Imagify, represents a significant advancement in cardiovascular diagnostics, addressing a critical need in the healthcare market. The growth outlook for Acusphere appears promising, with ongoing efforts to expand its product offerings and potential collaborations that could enhance its market presence. Financially, the company has demonstrated operational efficiency with a notable operating income margin, despite challenges reflected in net income figures. The liquidity position, supported by cash reserves, allows for continued investment in research and development, positioning Acusphere for future growth opportunities. Overall, Acusphere, Inc. presents a compelling case for potential investors interested in the pharmaceutical sector, particularly in innovative cardiovascular solutions.